NVO ▼ -5.9% - Novo Nordisk A/S $NVO investor meeting: Management says competition is at an unprecedented level for Novo, with “almost every other pharma company” targeting the obesity market and early signs of semaglutide loss of exclusivity already emerging in some markets Novo Nordisk shares fell 5.9% after management acknowledged intensifying competition in the obesity market, noting that rivals are aggressively pursuing the segment and that semaglutide—a key revenue driver—is already facing exclusivity challenges in certain markets. The admission of early generic and competitive pressure on one of the company's most important products appears to have triggered the selloff. 21-SEP-2026 05:27 AM ET